SIR -Schizophrenia is a complex and possibly heterogeneous mental disorder. The clinical presentation of the disease varies among affected individuals.
1 Heterogeneity of schizophrenia may bear a causal relationship to different biochemical disturbances which depend to a certain degree on genetic variation at the DNA level. Traditional linkage studies so far reported have failed to identify a single gene of major effect. Schizophrenia may be a polygenic illness.
Cytosolic phospholipase A2 (cPLA2) is the enzyme which cleaves the sn-2 ester linkage in membrane phospholipids preferentially liberating arachidonic acid (AA).
2 It has been found in all cells investigated to date and thus may play an important role in signal transduction processes, membrane remodelling, phospholipid and AA metabolism. Neuronal membranes are largely made up of phospholipids and therefore abnormalities of membrane phospholipids have been proposed as a biochemical basis for schizophrenia. 3, 4 Low levels of docosahexaenoic acid (DHA) and AA in phospholipids have been found in patients mainly manifesting negative syndromes of schizophrenia, 5 suggesting that increased activity of phospholipase A2, especially cPLA2, may in some cases be involved in schizophrenia. Evidence for the involvement of abnormal cPLA2 in schizophrenia has also been presented in several studies. 6, 7 Since there is no doubt that genetic factors contribute to the etiology of schizophrenia, the gene coding for cPLA2 could be considered as a candidate locus for schizophrenia. In a case-control study conducted with 36 unrelated Indian patients with schizophrenia and 27 unrelated Indian control subjects, we found that a BanI polymorphic site in the first intron of the cPLA2 gene was associated with schizophrenia. 8 The question necessarily addressed here is whether or not the association really reflects linkage between the cPLA2 gene and a locus for schizophrenia. To rule out a false-positive result from ethnic differences in the frequency distribution of the DNA marker or from the population structure, it was thought to be important to replicate the work in a different ethnic population and to conduct a family-based test. The present work was therefore undertaken to examine the association between the cPLA2 gene and schizophrenia with Caucasian DNA samples on the one hand, and with both population-based and family-based tests on the other hand. In the family-based study, the allele transmitted from parents to the affected offspring was used as a 'case' and that nontransmitted as a 'control', so as to form a genetically well-matched case-control sample.
One hundred and ninety-three unrelated schizophrenic individuals (129 males and 64 females) aged 36.1 ± 10.5 years, and 101 unrelated healthy control subjects (52 males and 49 females) aged 38.9 ± 12.6 years, were recruited in this study. They were all Caucasian. These patients had been diagnosed as having a schizophrenic illness by the psychiatrists who had treated them initially. Of these 193 patients, 50 came with both biological parents to take part in the genetic study. These 50 nuclear families were used for the haplotype-based haplotype relative risk (HHRR) test 9 and also for the transmission/disequilibrium test (TDT).
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All the subjects gave informed consent for taking blood samples, and genomic DNA was extracted from whole blood samples by using the Micromix 200 Kit (Talent, Italy). The sequence containing the BanI polymorphic site in the first intron of the cPLA2 gene was amplified by a polymerase chain reaction (PCR) process with a pair of primers, 5Ј CATGCCCGTAATAC-CAGCAC3Ј (sense strand) and 5Ј GCAAACAAGAT-GAATGGGAAC3Ј (antisense strand). BanI digestion of the PCR products gave two individual alleles, A1 and A2, which were identified by the absence (A1) or presence (A2) of the BanI site. Allelic frequencies were 0.35 (A1) and 0.65 (A2) in unrelated schizophrenic patients, and were 0.36 (A1) and 0.64 (A2) in unrelated controls. The distribution of genotypic frequencies was in Hardy-Weinberg equilibrium in both unrelated patients and unrelated control subjects. The chi-square ( 2 ) test did not show a significant difference in either allelic or genotypic frequencies between schizophrenic patients and control subjects. As shown in Table 1 , however, allelic frequency of the transmitted A2 was significantly higher than that of the nontransmitted ( 2 = 4.91, d.f. = 1, P = 0.027). Moreover, among these 50 nuclear families, 47 patients were heterozygous and had transmitted 16 A1 alleles and 31 A2 alleles to their affected offspring. The TDT statistic showed a significant difference ( 2 = 4.79, d.f. = 1, P = 0.029). In this study, we failed to replicate the result obtained from the Indian DNA samples using Caucasian DNA samples for a population-based association test. The population structure might have been a major reason for the inconsistent findings. However, the family-based study should give a more reliable result than a population-based study, as it is conducted with genetically well-matched samples. As mentioned above, both the HHRR test and TDT statistics revealed that allelic frequency of the transmitted A2 was significantly higher than that of the nontransmitted, suggest- ing that the cPLA2 gene may be associated with schizophrenia. The allelic association raises the possibility that the gene for human cPLA2 may either play a role in predisposing an individual to schizophrenia or be in linkage disequilibrium with a faulty locus for schizophrenia. Several studies have directly or indirectly demonstrated that abnormal cPLA2 may be involved in schizophrenia. [5] [6] [7] The functional polymorphism of the cPLA2 gene may therefore contribute to the pathogenesis of schizophrenia.
Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy
SIR -Intensive research has focused on the mechanism of Li's pharmacological actions and particularly on the phosphoinositide (PI) signal transduction cycle as the molecular substrate underlying this ion's clinical usefulness.
1 Following the demonstration that therapeutic concentrations of Li uncompetitively inhibit inositol monophosphatase (IMPase) activity, 2 it was proposed 2,3 that this ubiquitous enzyme which regenerates intracellular free inositol is a principal therapeutic target of Li. These considerations spurred us to examine the in vitro activity of IMPase in 106 transformed lymphoblastoid cell lines derived from control subjects and bipolar disorder (BPD) patients characterized by therapeutic response to Li.
As shown in Figure 1a , cell lines from bipolar patients had significantly lower IMPase activity than cell lines from control subjects (t-test: t = 9.16, P = 0.002, d.f. = 104). When the bipolar patients were grouped according to clinical response to Li therapy (Figure 1b) , the Li responders (BP Li R) exhibited significantly lower IMPase activity compared to those patients with poor Li response (BP Li NR) (t-test: t = 3.77, P = 0.00035, d.f. = 65). Similar results were obtained if the results were analyzed by simultaneously comparing mean scores of the three (control, BP Li R and BP Li NR) subject groups (one-way ANOVA: F = 6.497, P = 0.002, d.f. 2,93 ). Post-hoc Fisher's LSD comparison also showed that cell lines from the control group had significantly higher IMPase activity than cell lines from BP Li R (P = 0.001). BP Li R and BP Li NR cell lines also significantly differed (P = 0.046) whereas no significant post-hoc difference was observed between BP Li NR and control lines.
Considering the well-established in vitro inhibition of IMPase by therapeutic Li concentrations, 2 the results currently described appear counterintuitive. If Li is an inhibitor of IMPase, and Li is a mood-stabilizing drug, one would expect elevated IMPase levels in drug-free BPD patients. The current results suggest that the regulation of IMPase activity is more complicated and might be subject to transcriptional modulation. These considerations prompted us to examine the effect of chronic Li treatment at therapeutic concentrations on IMPase mRNA levels for the predominant brain form of this enzyme. [4] [5] [6] Five days of 1 mM Li treatment representing a minimum of two generations of growth in vitro (Figure 2) , significantly raised by 40% IMPase mRNA levels (t-test: t = 2.22, P = 0.029, d.f. = 116).
These results suggest that in BPD Li responders, who exhibit genetically determined low IMPase activity, chronic inhibition of this enzyme by Li therapy leads to transcriptional up-regulation of mRNA levels which may lead to normalized enzyme levels. A possible molecular mechanism for this Li effect is based on the presence of two adjacent consensus sequences in the 3Ј UTR of the human IMPase (IMPA) gene. 4 These two sequences are homologous to a 9-bp motif in the promoter region of some yeast genes, that represents a binding site for a regulatory factor. The factor is a complex of two proteins that together control the transcription of several phospholipid biosynthetic enzymes.
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This complex formation is favored in the absence of inositol. Li treatment, by inhibiting IMPase, results in low inositol levels, especially in Li-responding BP patients. The drop in inositol could, as in yeast, release the suppression of transcription and thus normalize enzyme translation and activity.
The observed difference in IMPase activity within the bipolar patient group suggests genetic heterogeneity in this complex disorder. A previous preliminary study in a small group of post-mortem bipolar patient brains found no reduction in IMPase activity, but drug treatment and agonal state were not controlled. 8 Neither parametric nor non-parametric linkage investigations of the major psychoses have achieved the
